The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.
about
Overview of extended release tacrolimus in solid organ transplantationGenetic variability in CYP3A5 and its possible consequences.Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.Ethnic disparities in liver transplantation.Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to AnalysisA review and assessment of potential sources of ethnic differences in drug responsiveness.Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients.The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipientsInfluence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects.Pharmacokinetic principles of immunosuppressive drugs.Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome.Cytochrome P450 3A polymorphisms and immunosuppressive drugs.Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.Pharmacokinetic variability of anticancer agents.Disparities in solid organ transplantation for ethnic minorities: facts and solutions.Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortiumGenotype-guided tacrolimus dosing in African-American kidney transplant recipients.Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.The role of tacrolimus in renal transplantation.Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients.Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation.Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.Impact of CYP3A5 and MDR-1 gene polymorphisms on the dose and level of tacrolimus among living-donor liver transplanted patients: single center experience.A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized.Pharmacogenetics of tacrolimus: ready for clinical translation?A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients.Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.Optimization of initial tacrolimus dose using pharmacogenetic testing.Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction.Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients.
P2860
Q26751450-22AAEBDF-A5E3-4153-9E85-8BF87CACB7F9Q30341330-C3FE1B60-D25B-4F29-8797-A3A25F1FB48FQ33977228-03B9314E-695B-4395-BC52-42E7F7E0A343Q34510280-E5AECCDE-4835-4834-A249-779F1A267D66Q35078994-AA5DFBEF-C291-4882-9E47-0C36C618BBE2Q35185164-4F5664B8-1B78-41F2-B189-F541E0665509Q35217493-64D26B54-E35E-4150-8EC4-8CE8C5358C16Q35415535-3C5D843F-AC7E-46C3-B9A6-1DBBB3EE47A3Q35612903-24873F4B-EE36-43CE-BC64-B96E337CBCDDQ35804046-110CCAA9-CA1B-4C50-8987-602CF0EA9836Q35876954-0C7E61A4-F713-41C4-8181-5C43CC27BB1EQ35946398-C0BB9DBC-644F-4394-9600-E9749C007DC7Q35987461-A68F7D83-3733-44A4-A437-A33297EC7D1CQ36006086-4C8ED27C-D407-41C1-9FFC-38454550CA75Q36029868-33E678E1-7498-4262-9D80-1D2D21C54723Q36050572-19FD4109-9380-4095-A4CA-FF6875208088Q36125433-828B6800-4AE4-4960-8051-1B174D5CCBA8Q36146910-665FF2F0-2C7E-49DD-9821-EAC10C7173F6Q36585295-E3C50840-A630-4B4D-9AF1-FBFC4BE72EA8Q36630081-2B159614-FA54-4C3F-ADFC-05D58D9189E5Q37009025-3A7E4329-DBF3-4C62-A72B-6827DE70D029Q37074093-D8688C22-6AFD-45C7-BAA1-E82BD7AF12E7Q37099023-16666D4C-F714-4782-B084-02889A1362C7Q37157896-FC4C552F-C13B-4089-A3C3-EC246B02D502Q37161904-80436AEA-F6E6-4B99-90FB-88F72FB3D5A2Q37892910-32929222-0A85-4A30-9684-FB31E2B3964BQ38163945-78A851B4-2CDC-4427-8938-FB2C536893DFQ38223136-E2312A2E-5E60-4B07-A87E-0F667A43A362Q38520159-CD174E4B-BE82-417C-BB75-D94F22CE899DQ38612229-FACBE7D7-36EE-49A9-8D5F-BEC6CC150599Q38748975-77A05663-A61E-4BFB-985F-A299DB9A2CEFQ39000636-21CB0573-8BEC-460C-8B61-849B9B5C4422Q39041618-E1452BA6-D311-4448-98B6-DD8DD22776B0Q40925162-BD0EB62E-7C87-4225-B06A-DDA40B3EA0E2Q42143648-9BB69B36-B8E0-4289-81DB-80CD2595A2D0Q42622920-8664DC4C-9000-42D1-AD79-AC9C3769EB01Q42837771-6770E2C1-ED51-44A7-A03F-C06629117B31Q43099038-CC13081B-590B-4DD5-9A38-8E6D1CF663E7Q43840252-5E18DF8A-DD73-41B5-A4C8-45737F69A78DQ43901935-FBA9F1DB-F638-4B9D-B90F-59718511ED42
P2860
The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The pharmacokinetics and metab ...... mparison across ethnic groups.
@ast
The pharmacokinetics and metab ...... mparison across ethnic groups.
@en
type
label
The pharmacokinetics and metab ...... mparison across ethnic groups.
@ast
The pharmacokinetics and metab ...... mparison across ethnic groups.
@en
prefLabel
The pharmacokinetics and metab ...... mparison across ethnic groups.
@ast
The pharmacokinetics and metab ...... mparison across ethnic groups.
@en
P2093
P356
P1476
The pharmacokinetics and metab ...... mparison across ethnic groups.
@en
P2093
Bekersky I
Christians U
Dressler D
Frassetto L
Mancinelli LM
P356
10.1067/MCP.2001.113183
P407
P577
2001-01-01T00:00:00Z